Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03343093 · ClinicalTrials.gov registry record · NA
Restore: Improving Sexual Outcomes of Gay and Bisexual Prostate Cancer Survivors
A NA study of Prostatic Neoplasm, sponsored by University of Minnesota.
- Completed
- Registry status
- NA
- Development phase
- 403
- Enrollment target
- 1
- Study location
NCT03343093 is a NA study of Prostatic Neoplasm that has completed, run by University of Minnesota. The registered enrollment target is 403 participants, above the 208-participant average among 9 other Prostatic Neoplasm trials with a reported enrollment target (94% higher). The trial reports 1 study location across 1 state.
The verdict
NCT03343093, a NA study of Prostatic Neoplasm, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- NA
- Development phase
- 403 participants
- Enrollment target
- 1
- Study location
Study Summary
Development and evaluation of an online intervention addressing sexual functioning in gay and bisexual men (GBM) after prostate cancer treatment.
Conditions Studied
Interventions
- BEHAVIORAL Control
- BEHAVIORAL Restore Rehabilitation Program
Study Locations (1)
Minnesota
- University of Minnesota Twin Cities Campus - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 403 participants |
| Start Date | 2019-01-01 |
| Est. Completion | 2023-06-20 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03343093
The ClinicalTrials.gov registry entry for NCT03343093 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 403 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 208-participant average among 9 other Prostatic Neoplasm trials with a reported enrollment target (94% higher). The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostatic Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which Control is the first listed.
NCT03343093 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT03343093 about?
NCT03343093 is a clinical study titled "Restore: Improving Sexual Outcomes of Gay and Bisexual Prostate Cancer Survivors". Development and evaluation of an online intervention addressing sexual functioning in gay and bisexual men (GBM) after prostate cancer treatment.
What is the current status of trial NCT03343093?
This trial is currently completed. It is a NA study. The enrollment target is 403 participants. The study started on 2019-01-01. Estimated completion is 2023-06-20.
What conditions does trial NCT03343093 study?
This clinical trial studies the following conditions: Prostatic Neoplasm.
What interventions are being tested in trial NCT03343093?
The interventions under investigation include: Control (BEHAVIORAL), Restore Rehabilitation Program (BEHAVIORAL).
Who is sponsoring clinical trial NCT03343093?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03343093 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostatic Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Investigation of Impact of AI on Prostate Cancer Workflow
RECRUITING · NA
-
Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors
COMPLETED · NA
-
Prostate Cancer Genetic Risk Evaluation and Screening Study
RECRUITING
-
A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC
ACTIVE NOT RECRUITING · Phase 2
-
Towards Understanding Between ADT Treatment, Circadian Rhythm, and Physiological Responsiveness
ACTIVE NOT RECRUITING · Phase 1
-
I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.